Glucose-6-phosphate dehydrogenase activity decreases during storage of leukoreduced red blood cells

Transfusion ◽  
2015 ◽  
Vol 56 (2) ◽  
pp. 427-432 ◽  
Author(s):  
Anna L. Peters ◽  
Robin van Bruggen ◽  
Dirk de Korte ◽  
Cornelis J.F. Van Noorden ◽  
Alexander P.J. Vlaar
Keyword(s):  
Red Blood Cells ◽  
Dehydrogenase Activity ◽  
Blood Cells ◽  
Glucose 6 Phosphate Dehydrogenase

THE EFFECT OF NECROGENIC DIETS ON THE ACTIVITIES OF CERTAIN ENZYME SYSTEMS IN THE RED BLOOD CELLS OF RATS

1964 ◽  
Vol 42 (12) ◽  
pp. 1809-1814 ◽  
Author(s):  
Beverley B. Lazier ◽  
J. M. R. Beveridge
Keyword(s):  
Red Blood Cells ◽  
Glutathione Reductase ◽  
Dehydrogenase Activity ◽  
Blood Cells ◽  
Sodium Selenite ◽  
Basal Diet ◽  
Hepatic Necrosis ◽  
Male Rats ◽  
Enzyme Systems ◽  
Glucose 6 Phosphate Dehydrogenase

The enzymic activities of glucose-6-phosphate dehydrogenase, glutathione reductase, and catalase were studied in the red blood cells of male rats which were fed a basal diet designed to induce acute hepatic necrosis. Significant decreases in the activity were found for all three systems. These changes were prevented by supplementing the basal diet with one of the following: methionine, sodium selenite, DL-α-tocopherol acetate, or all three factors plus cystine.There was no significant change in 6-phosphogluconic dehydrogenase activity when it was investigated under similar circumstances.

Oxidative Challenge and Glucose-6-Phosphate Dehydrogenase Activity of Preterm and Term Neonatal Red Blood Cells

Neonatology ◽  
2009 ◽  
Vol 96 (2) ◽  
pp. 96-101 ◽  
Author(s):  
Chun Hay Ko ◽  
Raymond Pui-On Wong ◽  
Pak Cheung Ng ◽  
Karen Li ◽  
Kit Man Chui ◽  
...  
Keyword(s):  
Red Blood Cells ◽  
Dehydrogenase Activity ◽  
Blood Cells ◽  
Oxidative Challenge ◽  
Glucose 6 Phosphate Dehydrogenase

scholarly journals The Course of Experimentally Induced Hemolytic Anemia in a Primaquine-Sensitive Caucasian

Blood ◽  
1965 ◽  
Vol 25 (1) ◽  
pp. 92-95 ◽  
Author(s):  
IVO PANNACCIULLI ◽  
ALBERTO TIZIANELLO ◽  
FRANCO AJMAR ◽  
EMANUELE SALVIDIO
Keyword(s):  
Red Blood Cells ◽  
Hemolytic Anemia ◽  
Blood Cells ◽  
Drug Induced ◽  
Glucose 6 Phosphate Dehydrogenase ◽  
Experimentally Induced

Abstract Two severe hemolytic crises, in a month’s period, were induced by primaquine in a glucose-6-phosphate dehydrogenase deficient Sardinian male. Young red blood cells tagged with Fe59 10 to 16 days earlier were destroyed in the second hemolytic episode. The implications of these experiments on the nature of drug-induced hemolysis in Caucasians are briefly discussed.

Drug‑induced hemolytic anemia

2021 ◽  
pp. 49-56
Author(s):  
O. D. Ostroumova ◽  
S. A. Bliznyuk ◽  
A. I. Kochetkov ◽  
A. G. Komarova
Keyword(s):  
Red Blood Cells ◽  
Hemolytic Anemia ◽  
Blood Cells ◽  
Antihypertensive Drugs ◽  
Drug Induced ◽  
Main Method ◽  
Hereditary Risk ◽  
Common Drug ◽  
Severity Of The Disease ◽  
Glucose 6 Phosphate Dehydrogenase

One of the reasons for the development of hemolytic anemia (HA) can be drugs, including some antibacterial, non-steroidal anti-inflammatory, antitumor and antihypertensive drugs. It was found that the most common drug-induced hemolytic anemia (DIHA) develops against the background of taking antibacterial drugs. The true prevalence of DIHA is not known and is approximately one case per 1.0–1.2 million patients. The mechanisms of the occurrence of DIHA are divided into immune and metabolic (non-immune). The first mechanism is associated with the formation of haptens, the second option – with the formation of immune complexes, the third option is mediated by the formation of true autoantibodies to red blood cells, the fourth option of the immune mechanism of the occurrence of DIHA is non-immunological protein absorption on the membranes of red blood cells. The risk factors for the development of DIHA are not fully established. The most common hereditary risk factor for DIHA is glucose-6-phosphate dehydrogenase deficiency. The main method of diagnosing DIHA is a direct antiglobulin test (direct Coombs’ test). The temporal relationship between the use of the inducer drug and the development of HA symptoms is important. The treatment strategy of DIHA is determined by the severity of the disease. In all cases, treatment should be initiated with the identification and withdrawal of the drug that initiated the occurrence of HA. With the development of severe HA, hemodialysis may be required. Prevention of DIHA involves avoiding the use of drugs associated with a high risk of its development.

Sign in / Sign up

Export Citation Format

Share Document